Keywords: myogen, reports, positive, ambrisentan, data, biopharmaceutical, firm

Myogen reports positive ambrisentan data

Article | 08 May 2006

US biopharmaceutical firm Myogen has announced the results of two pivotal Phase III trials evaluating ambrisentan, an oral endothelin receptor ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Drugs

Nystatin

Go to drug listing